Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TIRZEPATIDE Cause Urinary tract infection? 216 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 216 reports of Urinary tract infection have been filed in association with TIRZEPATIDE (Zepbound). This represents 0.2% of all adverse event reports for TIRZEPATIDE.

216
Reports of Urinary tract infection with TIRZEPATIDE
0.2%
of all TIRZEPATIDE reports
2
Deaths
62
Hospitalizations

How Dangerous Is Urinary tract infection From TIRZEPATIDE?

Of the 216 reports, 2 (0.9%) resulted in death, 62 (28.7%) required hospitalization, and 10 (4.6%) were considered life-threatening.

Is Urinary tract infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TIRZEPATIDE. However, 216 reports have been filed with the FAERS database.

What Other Side Effects Does TIRZEPATIDE Cause?

Incorrect dose administered (23,301) Injection site pain (10,989) Nausea (10,018) Off label use (7,007) Extra dose administered (6,774) Diarrhoea (5,463) Vomiting (4,635) Injection site haemorrhage (4,389) Accidental underdose (3,897) Injection site erythema (3,844)

What Other Drugs Cause Urinary tract infection?

ADALIMUMAB (6,375) LENALIDOMIDE (4,247) ETANERCEPT (3,915) OCRELIZUMAB (3,618) TOFACITINIB (3,179) METHOTREXATE (2,960) DALFAMPRIDINE (2,757) RITUXIMAB (2,579) CARBIDOPA\LEVODOPA (2,151) ABATACEPT (2,110)

Which TIRZEPATIDE Alternatives Have Lower Urinary tract infection Risk?

TIRZEPATIDE vs TISAGENLECLEUCEL TIRZEPATIDE vs TISLELIZUMAB TIRZEPATIDE vs TISOTUMAB VEDOTIN TIRZEPATIDE vs TISOTUMAB VEDOTIN-TFTV TIRZEPATIDE vs TITANIUM DIOXIDE\ZINC

Related Pages

TIRZEPATIDE Full Profile All Urinary tract infection Reports All Drugs Causing Urinary tract infection TIRZEPATIDE Demographics